Thursday, December 19, 2013

The Motley Fool: A Pain Specialist Buys a Technology Call Option

Endo Health Solutions (NASDAQ: ENDP  ) has not been shy about using M&A to rebuild its growth prospects in the wake of losing patent coverage on Lidoderm and Opana ER. While prior management didn't do well with its M&A, new management has already made some smart (albeit not necessarily cheap) deals for Paladin Labs and Boca Pharmaceutical. Now management is going for for a different sort of deal -- the acquisition of NuPathe (NASDAQ: PATH  ) is hardly a slam dunk value-adding deal, but the upfront consideration of $105 million excluding deal costs is not a terribly high price to pay for taking a chance.

Please follow this link:
A Pain Specialist Buys a Technology Call Option

No comments: